Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options

Current Opinion in HIV and AIDS

Volumn 5, Issue 1, 2010, Pages 27-37

  De Luca, Andrea ^a   Prosperi, Mattia ^a   Bracciale, Laura ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antiretroviral therapy; HIV 1 drug resistance; Low middle income countries; Therapeutic sequencing; Viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE SURVEILLANCE; DRUG DOSE SEQUENCE; DRUG MONITORING; GENOTYPE; HEALTH PROGRAM; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; INFECTION PREVENTION; MUTATIONAL ANALYSIS; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SCALE UP; SINGLE DRUG DOSE; STRATEGIC PLANNING; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; POVERTY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 74349117251     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328333ad45     Document Type: Review

References (75)

1. Consultation on technical and operational recommendations for scale-up of laboratory services and monitoring HIV antiretroviral therapy in resourcelimited settings. Geneva: World Health Organization; 2006.
2. Antiretroviral therapy for HIV infection in adults and adolescents in resourcelimited settings: towards universal access. Recommendations for a public health approach. Geneva: World Health Organization; 2006.
3. Renaud-Thery F, Nguimfack BD, Vitoria M, et al. Use of antiretroviral therapy in resource limited countries in 2006: distribution and uptake of first-and second-line regimens. AIDS 2007; 21 (Suppl 4):S89-S95.
4. Hamers RL, Derdelinckx I, van Vugt M, et al. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 2008; 13:625-639.
5. Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 (Suppl 2):25-36.
6. Yaotsè DA, Nicole V, Roch NF, et al. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drugresistance mutations in ARV naive patients. Infect Genet Evol 2009; 9:646-652.
7. Mintsa-Ndong A, Caron M, Plantier JC, et al. High HIV type 1 prevalence and wide genetic diversity with dominance of recombinant strains but low level of antiretroviral drug-resistance mutations in untreated patients in northeast Gabon, Central Africa. AIDS Res Hum Retroviruses 2009; 25:411-418.
8. Bá rtolo I, Casanovas J, Bastos R, et al. HIV-1 genetic diversity and transmitted drug resistance in healthcare settings in Maputo, Mozambique. J Acquir Immune Defic Syndr 2009; 51:323-331.
9. Abreu CM, Brindeiro PA, Martins AN, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 isolates circulating in pregnant women from Mozambique. Arch Virol 2008; 153:2013-2017.
10. Orrell C, Walensky RP, Losina E. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-531.
11. Bá rtolo I, Rocha C, Bartolomeu J, et al. Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance. Antimicrob Agents Chemother 2009; 53:3156-3158.
12. Derache A, Maiga AI, Traore O, et al. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 2008; 62:456-463.
13. Eshleman SH, Laeyendecker O, Parkin N, et al. Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS 2009; 27:845-852.
14. Kandathil AJ, Kannangai R, Abraham OC, et al. The frequency of HIV-I drug resistance mutations among treatment-naive individuals at a tertiary care centre in south India. Int J STD AIDS 2009; 20:522-526.
15. Tu YQ, Wang MJ, Yao J, et al. Human immunodeficiency virus-1 genotypic drug resistance among volunteer blood donors in Yunnan, China. Transfusion 2009; 449:1865-1873.
16. Ishizaki A, Cuong NH, Thuc PV. Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam. AIDS Res Hum Retroviruses 2009; 25:175-182.
17. Bennett DE, Camacho RJ, Otelea D. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4:e4724.
18. Maphalala G, Okello V, Mndzebele S, et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 2008; 13 (Suppl 2):95-100.
19. Somi GR, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008; 13 (Suppl 2):77-82.
20. Aghokeng AF, Vergne L, Mpoudi-Ngole E, et al. Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther 2009; 14:401-411.
21. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13 (Suppl 2):101-107.
22. Abegaz WE, Grossman Z, Wolday D, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther 2008; 13 (Suppl 2):89-94.
23. Kamoto K, Aberle-Grasse J, Malawi HIV Drug Resistance Task Force. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008; 13 (Suppl 2):83-87.
24. Ndembi N, Lyagoba F, Nanteza B, et al. Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. AIDS Res Hum Retrovir 2008; 24:889-895.
25. Chen X, Xing H, He JM, et al. Study on the threshold of HIV-1 drug resistance in Hunan province. Zhonghua Liu Xing Bing Xue Za Zhi 2008; 29:787-789.
26. Nguyen HT, Duc NB, Shrivastava R, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther 2008; 13 (Suppl 2):115-121.
27. Sirivichayakul S, Phanuphak P, Pankam T, et al. HIV drug resistance transmission threshold survey in Bangkok, Thailand. Antivir Ther 2008; 13 (Suppl 2): 109-113.
28. World Health Organization. HIV Drug Resistance Prevention, Surveillance and Monitoring in the Western Pacific Region. Available at http://www. wpro.who.int/internet/resources.ashx/HSI/docs/HIV+Drug+Resistance+ Surveillance.pdf.
29. Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T, et al. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV. Clin Infect Dis 2009; 49:299-305.
30. Nyombi BM, Holm-Hansen C, Kristiansen KI, et al. Prevalence of reverse transcriptase and protease mutations associated with antiretroviral drug resistance among drug-naïve HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania. AIDS Res Ther 2008; 5: 13.
31. Kiptoo M, Ichimura H, Wembe RL. Prevalence of nevirapine-associated resistance mutations after single dose prophylactic treatment among antenatal clinic attendees in north rift Kenya. AIDS Res Hum Retroviruses 2008; 24:1555-1559.
32. Basson AE, Ntsala M, Martinson N, et al. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2008; 49:538-543.
33. Church JD, Mwatha A, Bagenda D, et al. In utero HIV infection is associated with an increased risk of nevirapine resistance in Ugandan infants who were exposed to perinatal single dose nevirapine. AIDS Res Hum Retroviruses 2009; 25:673-677.
34. Church JD, Omer SB, Guay LA, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 2008; 198:1075-1082.
35. Martinson NA, Morris L, Johnson J, et al. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS 2009; 27:809-816.
36. Flys TS, McConnell MS, Matovu F, et al. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis 2008; 198:465-469.
37. Foster C, Lyall H, Olmscheid B, et al. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med 2009; 10:397-406; Epub 2009 May 12.
38. Han J, Wang L, Jiang Y. Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China. Int J STD AIDS 2009; 20:249-254.
39. Lehman DA, Chung MH, Mabuka JM, et al. Lower risk of resistance after shortcourse HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr 2009; 51:522-529.
40. Arrivé E, Chaix ML, et al. TEmAA ANRS 12109 Study group, Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS 2009; 27:825-833.
41. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192:30-36.
42. Hauser A, Mugenyi K, Kabasinguzi R. Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR. Antimicrob Agents Chemother 2009; 53:2965-2973.
43. Wind-Rotolo M, Durand C, Cranmer L, et al. Identification of nevirapineresistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis 2009; 199:1301-1309.
44. Kuhn L, Semrau K, Ramachandran S, et al. Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. J Acquir Immune Defic Syndr 2009; 52:132-136.
45. Coovadia A, Hunt G, Abrams EJ. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48:462-472.
46. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
47. Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention and switch to second-line regimens in antiretroviral-treated patients in Sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis 2009; 48:115-122.
48. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
49. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-417.
50. Elliott JH, Lynen L, Calmy A, et al. Rational use of antiretroviral therapy in lowincome and middle-income countries: optimizing regimen sequencing and switching. AIDS 2008; 22:2053-2067.
51. Jordan MR, Bennett DE, Bertagnolio S, et al. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13 (Suppl 2):15-23.
52. Kouanfack C, Montavon C, Laurent C, et al. Low levels of antiretroviralresistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009; 48:1318-1322.
53. Kumarasamy N, Madhavan V, Venkatesh KK, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis 2009; 49:306-309.
54. Soria A, Porten K, Fampou-Toundji JC, et al. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther 2009; 14:339-347.
55. Steegen K, Luchters S, Dauwe K, et al. Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. AIDS Res Ther 2009; 6:12.
56. Hanson DL, Adjé-Touré C, Talla-Nzussouo N, et al. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire. AIDS Res Hum Retroviruses 2009; 25:489-495.
57. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
58. Tebit DM, Sangaré L, Makamtse A, et al. HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso. J Acquir Immune Defic Syndr 2008; 49:17-25.
59. Pillay V, Pillay C, Kantor R, et al. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:1449-1454.
60. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-1597.
61. Hawkins CA, Chaplin B, Idoko J, et al. Clinical and genotypic findings in HIVinfected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2009 [Epub ahead of print].
62. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, et al. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 2009; 200:687-697.
63. Uy J, Armon C, Buchacz K, et al. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009; 51:450-453.
64. Gottlieb GS, Badiane NM, Hawes SE, et al. Emergence of multiclass drugresistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. Clin Infect Dis 2009; 48:476-483.
65. Adlington R, Richens J, Shahmanesh M. First line antiretroviral therapy in resource-limited settings: time to reconsider? JID 2009; 199:1407.
66. Elliott JH, Pujari S. Protease inhibitor therapy in resource-limited settings. Curr Opin HIV AIDS 2008; 3:612-619.
67. Pinheiro Edos S, Antunes OA, Fortunak JM. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. Antiviral Res 2008; 79:143-165.
68. Lapadula G, Calabresi A, Castelnuovo F, et al. Prevalence and risk factors for etravirine resistance among patients failing on nonnucleoside reverse transcriptase inhibitors. Antivir Ther 2008; 13:601-605.
69. Geretti AM, Harrison L, Green H, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48:1296-1305.
70. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 nonsubtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009; 12:11.
71. Coutsinos D, Invernizzi CF, Xu H, et al. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009; 83:2029-2033; Epub 2008 Dec 10.
72. Margot NA, Enejosa J, Cheng AK, et al. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 2009 [Epub ahead of print].
73. Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Mé decins Sans Frontiè res. AIDS 2008; 22:1305-1312.
74. ProsperiMCF, Rosen-Zvi M, Altmann A, et al. Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history-based models. VII European HIV Drug Resistance Workshop, Stockholm, Sweden, 25-27 March 2009. Rev Antiviral Ther 2009; 1 (abstract 29):28-29.
75. Revell AD, Wang D, Harrigan R, et al. Computational models developed without a genotype for resource-poor countries predict response to HIV treatment with 82% accuracy. XVIII International HIV Drug Resistance Workshop, Fort Myers, Florida, USA, 9-13 June 2009.